ArticleScientific reports2025
Eco-friendly spectrofluorimetric and HPLC-fluorescence methods for simultaneous determination of melatonin and zolpidem in pharmaceuticals.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two eco-friendly, facile, rapid, and highly sensitive analytical methodologies were developed for the concurrent estimation of melatonin and zolpidem tartrate in raw materials and dosage forms. The first approach is a green first derivative synchronous spectrofluorimetric method (Method I), utilizing a wavelength interval (Δλ) of 60 nm and capturing derivative signals at 265.0 nm and 339.0 nm for melatonin and zolpidem, respectively. Method I exhibited excellent linearity over the ranges of 8.0-70.0 ng/mL for melatonin and 10.0-80.0 ng/mL for zolpidem, with detection limits of 1.62 ng/mL and 1.19 ng/mL. The second method (Method II) involves high-performance liquid chromatography coupled with fluorescence detection (HPLC-FD), employing a C18 column and a mobile phase of methanol:0.05% triethylamine (70:30, v/v, pH 5.5) at a flow rate of 1.0 mL/min. Fluorescence detection was performed at 383 nm following excitation at 243 nm. This method achieved linearity within 150.0-1500.0 ng/mL for melatonin and 50.0-700.0 ng/mL for zolpidem, with detection limits of 18.87 ng/mL and 8.86 ng/mL, respectively. Both methods were rigorously validated in accordance with ICH Q2(R1) guidelines, demonstrating high accuracy, precision, and robustness in analyzing commercial dosage forms. Greenness and sustainability were quantitatively assessed using the AGREE and eco-scale metrices, while method applicability and performance were evaluated using the Blue Applicability Grade Index (BAGI), affirming both techniques as efficient and environmentally sustainable tools for routine quality control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.